Literature DB >> 2233879

Functional testing.

R T Moxley1.   

Abstract

Functional testing is useful to monitor the natural history of several neuromuscular disorders, and to measure the efficacy of therapeutic agents in clinical trials. A major limitation of functional testing is that a single test is often not appropriate throughout all stages of disease. The same limitation holds true for other measurements of disease progression. MMT and quantitative myometry become technically difficult to perform and lack sensitivity to disease progression at some stages in the course of DMD, ALS, and spinal muscular atrophy. Other limitations of functional testing are its lack of sensitivity to detect a subtle improvement or decline in muscle strength, and the difficulty of applying standard statistical methods to analyze disease progression or therapeutic efficacy. The advantages of functional testing outweigh the limitations. Function testing uses daily activities to monitor disease progression. Patient's appreciate improvements in function more readily than improvements in muscle strength. Functional testing is easily standardized and is reliable. It can be performed, with little or no expense, in almost any clinical setting. The primary challenge for investigators who wish to incorporate functional tests is to identify functional tests that best measure the natural history of the specific disease under investigation. Further, functional testing allows the clinician to provide an educated guess on the likely future course of disease.

Entities:  

Mesh:

Year:  1990        PMID: 2233879     DOI: 10.1002/mus.880131309

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  8 in total

1.  A modified Hammersmith functional motor scale for use in multi-center research on spinal muscular atrophy.

Authors:  Kristin J Krosschell; Jo Anne Maczulski; Thomas O Crawford; Charles Scott; Kathryn J Swoboda
Journal:  Neuromuscul Disord       Date:  2006-06-05       Impact factor: 4.296

2.  Facioscapulohumeral muscular dystrophy: a prospective study of weakness and functional impairment.

Authors:  Joerg-Patrick Stübgen; Annette Stipp
Journal:  J Neurol       Date:  2010-03-30       Impact factor: 4.849

3.  Reliability of the Modified Hammersmith Functional Motor Scale in young children with spinal muscular atrophy.

Authors:  Kristin J Krosschell; Charles B Scott; Jo Anne Maczulski; Aga J Lewelt; Sandra P Reyna; Kathryn J Swoboda
Journal:  Muscle Nerve       Date:  2011-06-22       Impact factor: 3.217

4.  Facioscapulohumeral muscular dystrophy functional composite outcome measure.

Authors:  Katy Eichinger; Chad Heatwole; Stanley Iyadurai; Wendy King; Lindsay Baker; Susanne Heininger; Amy Bartlett; Nuran Dilek; William B Martens; Michael Mcdermott; John T Kissel; Rabi Tawil; Jeffrey M Statland
Journal:  Muscle Nerve       Date:  2018-01-30       Impact factor: 3.217

5.  Reliability of the adult myopathy assessment tool in individuals with myositis.

Authors:  Michael O Harris-Love; Galen Joe; Todd E Davenport; Deloris Koziol; Kristen Abbett Rose; Joseph A Shrader; Olavo M Vasconcelos; Beverly McElroy; Marinos C Dalakas
Journal:  Arthritis Care Res (Hoboken)       Date:  2015-04       Impact factor: 4.794

6.  Motor function performance in individuals with RYR1-related myopathies.

Authors:  Jessica W Witherspoon; Carole Vuillerot; Ruhi P Vasavada; Melissa R Waite; Monique Shelton; Irene C Chrismer; Minal S Jain; Katherine G Meilleur
Journal:  Muscle Nerve       Date:  2019-07       Impact factor: 3.217

Review 7.  Outcome Measures in Facioscapulohumeral Muscular Dystrophy Clinical Trials.

Authors:  Mehdi Ghasemi; Charles P Emerson; Lawrence J Hayward
Journal:  Cells       Date:  2022-02-16       Impact factor: 6.600

8.  Clinical trial readiness to solve barriers to drug development in FSHD (ReSolve): protocol of a large, international, multi-center prospective study.

Authors:  Samantha LoRusso; Nicholas E Johnson; Michael P McDermott; Katy Eichinger; Russell J Butterfield; Elena Carraro; Kiley Higgs; Leann Lewis; Karlien Mul; Sabrina Sacconi; Valeria A Sansone; Perry Shieh; Baziel van Engelen; Kathryn Wagner; Leo Wang; Jeffrey M Statland; Rabi Tawil
Journal:  BMC Neurol       Date:  2019-09-10       Impact factor: 2.474

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.